Can-Fite BioPharma Ltd. CANF 深 沪
已收盘 05-15 16:00:00 美东时间
3.36
-0.130
-3.72%
华盛通- 最 高3.495
- 今 开3.49
- 成交量 2.16万股
- 最 低 3.34
- 昨 收 3.49
- 总市值 719.90万
- 52周最高 23.40
- 市盈率 静 --
- 换手率 1.01%
- 52周最低 2.83
- 委 比 -33.33%
- 总股本 214.25万
- 历史最高 28380.00
- 量 比 0.36
- 振 幅 4.44%
- 历史最低 3.34
- 每 手 1
- 风险率 6.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
HC Wainwright & Co. Maintains Buy on Can Fite Biopharma, Raises Price Target to $5
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Can Fite Biopharma (AMEX:CANF) with a Buy and raises the price target from $2.5 to $5.
05-12 18:36
Can-Fite BioPharma Announces Its Phase 2a Trial Of Namodenoson In Advanced Pancreatic Cancer Participants Demonstrates Over 30% Of Patient Had Stable Disease Observed, Preliminary Evidence Of Clinical Activity, Favorable Safety And Tolerability Profile
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced
04-30 20:43
Can-Fite Biopharma's Veterinary Partner Vetbiolix Completes Enrollment In Phase 2 Study Of Piclidenoson For Osteoarthritis In Dogs; Topline Data Are Expected In Q3 2026
Vetbiolix, Can-Fite's veterinary commercialization partner, is funding all development costs associated with the registration of Piclidenoson for osteoarthritis in companion animals.Vetbiolix has exercised its option to
03-30 19:25
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
Can-Fite signed a $325M deal with Vetbiolix for their veterinary arthritis drug Piclidenoson. The Phase 2 study in dogs with osteoarthritis has completed enrollment, with results expected Q3 2026. The drug, which showed success in human psoriasis, is being developed for a $3B market.
03-30 11:20
Can‑Fite BioPharma Secures Israeli Patent Allowance For A3AR Agonists, Covering Namodenoson In Obesity And Fat‑Loss Use
Strengthens global IP and supports strategic positioning in the rapidly growing metabolic therapeutics marketRamat Gan, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a
03-17 19:49
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
Can-Fite BioPharma Ltd. announced that the Israeli Patent Office has allowed its patent application No. 284463, titled “An A3 Adenosine Receptor Ligand for Use for Achieving a Fat Loss Effect.” The patent covers the use of A3 adenosine receptor (A3AR) agonists, including Namodenoson, Can-Fite’s lead drug candidate, for inducing fat loss and treating obesity and related metabolic disorders. This allowance strengthens Can-Fite’s global intellectual...
03-17 11:47
Market-Moving News for March 4th
MRNA: 11% | Moderna shares are trading higher after the company announced that it has entered into a settlement agreement with Arbutus Biopharma and Genevant Sciences. CANF: 54% | Can-Fite
03-04 20:20
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Can Fite Biopharma (AMEX:CANF) stock rose 17.6% to $5.88 during Wednes...
03-04 20:05
